Anders Vahlne has been appointed managing director

Anders Vahlne has been appointed managing director As previously announced, Tripep AB is in the process of recruiting a new managing director. Johan Ihre, the current managing director, is finishing in his position today. Professor Anders Vahlne, a member of the board and one of the founders of Tripep, has been appointed new managing director pending the completion of the recruiting process. For more information, please contact: Anders Vahlne, CEO Head of Research Phone +46 8-5858 1313, mobile +46 709-28 05 28 E-mail: anders.vahlne@labmed.ki.se or Rolf L Nordström, Chairman of the Board mobil: 0044-777 613 7400 E-mail: rolf.l.nordstrom@btinternet.com Tripep is a biotech research company that develops and commercialises candidate drugs based on patented and patent-pending technologies: -research and development of alphaHGA, a HIV-inhibiting drug, -preclinical research focusing on the development of therapeutic and prophylactic vaccines against HIV and hepatitis C, and the RAS® technology platform. -producing vaccines against influenza, allergies and Alzheimer's disease through associated company VLP Biotech Inc. More details on Tripep's technologies are available at its Website: www.tripep.se ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2004/06/30/20040630BIT20610/wkr0001.pdf http://www.waymaker.net/bitonline/2004/06/30/20040630BIT20610/wkr0003.doc

About Us

ChronTech has developed and further develops a patent pending new type of injection needle for a more effective uptake of genetic vaccines (IVIN) and vaccine and therapy for hepatitis D. ChronTech also have part ownership in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium Nordic AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se.

Subscribe